Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...

Novartis said on Tuesday it had received approval in Switzerland for Coartem Baby, which it said was the first drug to treat ...

The approval of the first malaria treatment for newborns and young infants could lead to imminent widespread use in Africa, ...

The newly approved medication, Coartem Baby, is a combination of two antimalarials. It is a lower dose version of a tablet ...

The new drug, developed by Novartis and MMV, isn't a malaria vaccine, but can help treat babies with the disease.

Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.

Coartem Baby contains two medicines — artemether and lumefantrine — that work together to fight the malaria parasite. These ...

The pharmaceutical industry is criticizing the Trump administration’s plan for carrying out a critical round of Medicare drug ...

The first malaria treatment for newborns and young infants has received approval from Swiss health regulators, with eight ...

Swiss medicines regulator Swissmedic has approved Coartem Baby, a Novartis anti-malaria drug developed for infants weighing ...

Novartis and a Swiss nonprofit have made history, scoring the world’s first approval for a medicine to treat babies who are ...

Novartis has won approval in Switzerland for the world’s first malaria drug for newborns and infants, creating a new weapon in the fight against the mosquito-borne disease that is deadliest for ...